ernstig zieke IC patienten amino acid metabolism in the critically ill patient
Conditions
Interventions
Group 1 (control group): patients will receive enteral tube feeding, containing
1.5 g/kg protein/day ( including 0,15 g/kg/day glutamine) for at least 5 days.
Group 2 (treatment group): patients wil
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: *Age: > 18 and 18,5 and 200, PEEP
Exclusion criteria
Exclusion criteria: * Admission after elective surgery * Pregnancy * Liver failure, defined by bilirubin levels > 100 * Kidney failure, represented by increase in serum creatinine levels to > 100 umol/l, in the absence of primary underlying renal disease, or oliguria, defined as urine output 7. mg/ day > 3 weeks) * Bowel malabsorption possibly interfering with intestinal absorptive function, e.g. celiac disease, crohn*s disease, presence of fistulas, major intestinal malabsorption disorder, or short bowel syndrome * Parenteral feeding * Use of medium chain triglycerides or glutamine/citrulline supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The whole body rate of appearance of glutamine, citrulline and arginine, as well as the conversion of endogenous and exogenous, enteral supplied glutamine into citrulline and arginine at the whole body level. | — |
Secondary
| Measure | Time frame |
|---|---|
| First pass effect of the gut will be calculated using the difference between the whole body rate of appearance of glutamine when the glutamine tracer is given intravenously or enterally. | — |
Countries
Netherlands
Outcome results
None listed